CoChat

Hemolytic Potential of Tafenoquine in Female Volunteers Heterozygous for Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency (G6PD Mahidol Variant) versus G6PD-Normal Volunteers

Rueangweerayut, Ronnatrai, Bancone, Germana, Harrell, Emma J., Beelen, Andrew P., Kongpatanakul, Supornchai, Möhrle, Jörg J., Rousell, Vicki, Mohamed, Khadeeja, Qureshi, Ammar, Narayan, Sushma, Yubon, Nushara, Miller, Ann, Nosten, François H., Luzzatto, Lucio, Duparc, Stephan, Kleim, Jörg-Peter, Green, Justin A. · 2017 · The American Journal of Tropical Medicine and Hygiene
Cited by 100

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

Tafenoquine is an 8-aminoquinoline under investigation for the prevention of relapse in Plasmodium vivax malaria. This open-label, dose-escalation study assessed quantitatively the hemolytic risk with tafenoquine in female healthy volunteers heterozygous for the Mahidol 487A glucose-6-phosphate dehydrogenase (G6PD)-deficient variant versus G6PD-normal females, and with reference to primaquine. Six G6PD-heterozygous subjects (G6PD enzyme activity 40–60% of normal) and six G6PD-normal subjects per treatment group received single-dose tafenoquine (100, 200, or 300 mg) or primaquine (15 mg × 14 days). All participants had pretreatment hemoglobin levels ≥ 12.0 g/dL. Tafenoquine dose escalation stopped when hemoglobin decreased by ≥ 2.5 g/dL (or hematocrit decline ≥ 7.5%) versus pretreatment values in ≥ 3/6 subjects. A dose–response was evident in G6PD-heterozygous subjects ( N = 15) receiving tafenoquine for the maximum decrease in hemoglobin versus pretreatment values. Hemoglobin declines were similar for tafenoquine 300 mg (−2.65 to −2.95 g/dL [ N = 3]) and primaquine (−1.25 to −3.0 g/dL [ N = 5]). Two further cohorts of G6PD-heterozygous subjects with G6PD enzyme levels 61–80% ( N = 2) and > 80% ( N = 5) of the site median normal received tafenoquine 200 mg; hemolysis was less pronounced at higher G6PD enzyme activities. Tafenoquine hemolytic potential was dose dependent, and hemolysis was greater in G6PD-heterozygous females with lower G6PD enzyme activity levels. Single-dose tafenoquine 300 mg did not appear to increase the severity of hemolysis versus primaquine 15 mg × 14 days.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.4269/ajtmh.16-0779

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 4

  1. Battle, 2012, The global public health significance of Plasmodium vivax, 80, 1, 10.1016/B978-0-12-397900-1.00001-3 · DOI
  2. John, 2012, Primaquine radical cure of Plasmodium vivax: a critical review of the literature, 11, 280
  3. Howes, 2013, G6PD deficiency: global distribution, genetic variants and primaquine therapy, 81, 133, 10.1016/B978-0-12-407826-0.00004-7 · DOI · Paper page
  4. LaRue, 2014, 91, 854

Cited by

See all 100

Metadata

Authors
Rueangweerayut, R., Bancone, G., Harrell, E. J., Beelen, A. P., Kongpatanakul, S., Möhrle, J. J., Rousell, V., Mohamed, K., Qureshi, A., Narayan, S., Yubon, N., Miller, A., Nosten, F. H., Luzzatto, L., Duparc, S., Kleim, J.-P., & Green, J. A.
Affiliations
  • Department of Internal Medicine, Mae Sot General Hospital, Mae Sot, Thailand;
  • Shoklo Malaria Research Unit, Mahidol–Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Mae Sot, Thailand;
  • GlaxoSmithKline Research and Development Ltd., Uxbridge, United Kingdom;
  • GlaxoSmithKline, Research Triangle Park, North Carolina;
  • Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand;
  • Medicines for Malaria Venture, Geneva, Switzerland;
  • GlaxoSmithKline, Bangkok, Thailand;
  • GlaxoSmithKline, King of Prussia, Pennsylvania;
  • Istituto Toscano Tumori, Florence, Italy;
Venue
The American Journal of Tropical Medicine and Hygiene
Published
2017-09-07
Volume
97
Issue
3
Pages
702-711
ISSN
  • 0002-9637
  • 1476-1645
Cited by
100
References
1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.